Research programme: Alzheimer's disease prophylactics - Modgene

Drug Profile

Research programme: Alzheimer's disease prophylactics - Modgene

Alternative Names: imatinib para-diaminomethylbenzene trihydrochloride

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ModGene Pharma
  • Class Neuroprotectants
  • Mechanism of Action Amyloid beta-protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 19 Jul 2017 Research programme: Alzheimer's disease therapeutics - Modgene is available for licensing as of 19 Jul 2017. www.modgenepharmallc.com
  • 19 Jul 2017 Modgene has patent protection for Alzheimer's disease therapeutics (Prevention) in USA
  • 19 Jul 2017 Preclinical trials in Alzheimer's disease (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top